Cryotherapy Startup Arbel Medical in Second Round

Last month we reported on Core Dynamics, a company that develops technology to freeze human organs and increase their shelf life. Another Israeli startup, Arbel Medical, is developing office-friendly, next-generation , minimally invasive Cryo-therapy products for the treatment of breast tumors and other internal diseased tissue.

Founded in 2005, the company has previously raised $2.75 million in funding from Giza Venture Capital, Ofer Hi-Tech Ventures and TRD Instrum, and has now added an additional $450,000 from Bridge Investment Fund, which aims to set-up operations for Israeli life science companies in Cleveland, Ohio. Arbel is conducting trials in Cleveland and possibly opening offices there.

The company offers the following description of its flagship product IceSense:

“Cryotherapy is a fast-developing minimally-invasive procedure, in which a cryoprobe is used to ablate diseased tissue through the application of extreme cold.

IceSense™, Arbel’s breakthrough N2-based platform is adapted for use both in operating theaters and in freestanding clinics, offering the following key advantages over classical Joule-Thomson based products:

  • User friendliness (operation and maintenance) and reduced cost
  • Higher freezing capacity resulting in shorter treatment time
  • Easier control over the ablation process”

The company has future sights set on the growing area of women’s health, including using its IceSense technology in treating tumors from breast cancer, and also using it for aesthetic applications.